Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.030
-0.040 (-3.74%)
At close: Mar 28, 2025, 4:00 PM
1.040
+0.010 (0.98%)
After-hours: Mar 28, 2025, 7:55 PM EDT

Company Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.

The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

The company’s lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.

The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.

Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Werewolf Therapeutics, Inc.
Werewolf Therapeutics logo
Country United States
Founded 2017
IPO Date Apr 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Daniel Hicklin

Contact Details

Address:
200 Talcott Ave, 2nd Floor
Watertown, Massachusetts 02472
United States
Phone 617 952 0555
Website werewolftx.com

Stock Details

Ticker Symbol HOWL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001785530
CUSIP Number 95075A107
ISIN Number US95075A1079
Employer ID 82-3523180
SIC Code 2834

Key Executives

Name Position
Dr. Daniel J. Hicklin Ph.D. Founder, Chief Executive Officer, President, Secretary and Director
Timothy W. Trost CPA Chief Financial Officer, Treasurer and Assistant Secretary
Dr. Randi Isaacs M.D. Chief Medical Officer
Dr. William Winston Ph.D. Senior Vice President of Research
Dr. Chulani Karunatilake Ph.D. Chief Technology Officer
Ellen A. Lubman M.B.A. Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 11, 2025 424B5 Filing
Mar 11, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals